Location out of bounds


All Investigators
Thomas C Abshire, MD

Thomas Abshire, MD

Exec VP, MSI, CMO Versiti
Senior Investigator, BRI
Thrombosis, Hemostasis & Vascular Biology

Chief Medical Officer

Senior Investigator
Versiti Blood Research Institute

Professor of Pediatrics and Medicine
Medical College of Wisconsin

Contact Us

Thomas Abshire, MD

Exec VP, MSI, CMO Versiti
Senior Investigator, BRI
Thrombosis, Hemostasis & Vascular Biology
Email Phone: (414) 937-6434 Fax: (414) 933-6803

  • Research Interests

    Clinical trials in hemostasis and thrombosis including laboratory evaluation, therapeutic intervention and new product development. More recently, my focus has been in the evaluation of mild bleeding disorders and clinical trials in von Willebrand Disease (VWD).

  • Grant Support

    Sponsor: Rho, Inc    Abshire, Thomas C and Berntorp, Erik (Multiple PIs)    07/01/06-present
    von Willebrand Disease Prophylaxis Network (VWD PN) and the VWD International Prophylaxis (VIP) Study 
    Description: Determine the safety and efficacy of prophylaxis in VWD

    Role: Principal Investigator
    Sponsor: NIH/NHLBI,1R01 HL11264-01A1
    Montgomery, Robert R and Abshire, Thomas C (Multiple PIs)   2013-05/31/2018
    Comparitive Effectiveness in the Diagnosis of VWD
    Role: Principal Investigator

  • Publications
    • Werner EJ, Abshire TC, Giroux DS, Tucker EL, Broxson EH. The relative value of diagnostic studies for von Willebrand disease. J Pediatr, 1992; 121:34-38.
    • Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multi-ethnic study. J Pediatr 1993; 123(6): 893-898.
    • Abshire TC, Pollock BH, Billett AL, Bradley P, and Buchanan GR. Weekly polyethylene glycol (PEG) conjugated L-asparaginase produces superior induction remission rates childhood relapsed acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group (POG) Study. Blood 2000;96(5): 1709-1715
    • Abshire TC, Brackmann H-H, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic Factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Results of a Multicenter, International Clinical Investigation. Thromb Haemost 2000; 83(6):811-816.
    • Dunn AL, Busch MT, Wyly JB and Abshire TC for the Radionuclide Synovectomy in Hemophilia (RASH) Study Group. Radionuclide synovectomy for hemophilic arthropathy: A comprehensive review of safety and efficacy and the recombination for a standardized treatment protocol, for Thromb Haemost 2002; 87(3): 383-93.
    • Fried MW, Peter J, Hoots K, Gaglio P, Talbut D, Mathew P, Davis PC, Key N, White GC, Lindblad L, Rickles F and Abshire TC, for the Hemophilia Hepatitis Therapy Group. Hepatitis C in adults and adolescents with hemophilia and inherited coagulation disorders: a randomized, controlled, multicenter trial of combination therapy with Interferon alfa-2b and Ribavirin, Hepatology 2002; 36(4): 967-72.
    • Dunn AL, Busch M, Wyly JB, Sullivan K, Peter J and Abshire TC. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop 2004; 24(4): 414-26.
    • Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA and Neufeld EJ. Pediatric Rituximab/ITP Study Group and the Glazer Pediatric Research Network. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006 Apr 1;107(7):2639-42. PMCID: PMC1895391.
    • Kempton CL, Soucie JM and Abshire TC. Incidence of Inhibitors in a Cohort of 838 Males with Hemophilia A Previoiusly Treated with Factor VIII Concentrates. J Thromb Haemost, 2006 Dec;4(12): 2576-81.
    • Berntorp E, Abshire T: von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 2006 Nov;4(11):2511-2.
    • Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Funk S, Jacobson L, Valentino LA, Hoots WD, Buchanan GR, DiMichele D, Recht M, Brown D, Leissenger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med, 2007 Aug 9; 357(6):535-44.
    • Veil KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. Inhibitors of Factor VIII in Black Hemophilia Patients. N Engl J Med, 2009 Apr 16; 360(16):1618-27. PMCID: PMC2761028.
    • Flood VH, Gill JC, Morateck PA, Chirstopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffman RG, Abshire TC, DiPaola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010 July15; 116(2):280-6. PMCID: PMC2910611.
    • Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D; on behalf of the ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC Bleeding Assessment Tool: A Standardized Questionnaire and a Proposal for a New Bleeding Score for Inherited Bleeding Disorders. J Thromb Haemost. 2010 Sep; 8(9):2063-5. PMC Journal – In Process.
    • Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC. In non-severe hemophilia A the risk of inhibitor following intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010 Oct 8(10):2224-31. PMC Journal – In Process
    • Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators. J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11. PMID: 25354263.
    • Makris M, Federici AB, Mannucci PM, Bolton-Maggs PH, Yee TT, Abshire T, Berntorp E. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2014 Nov 7. doi: 10.1111/hae.12571. Epub ahead of print. PMID: 25381842.
    • Holm E, Abshire TC, Bowen J, Alvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015 Feb 27. Epub ahead of print.
    • Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. Multicenter randomized controlled trial on duration of therapy for thrombosis in children and young adults (Kids-DOTT): Pilot/Feasibility Phase Findings. J Thromb Haemost. 2015 Jun; 28. doi: 10.0000/jth.13038. [Epub ahead of print]. PMID: 26118944.
    • Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH; Hemophilia Inhibitor Research Study Investigators. Evaluation of von Willebrand factor phenotypes and genotypes in hemophilia A patients with and without identified F8 mutations. J Thromb Haemost. 2015 Jun;13(6):1036-42. doi: 10.1111/jth. 12902. Epub 2015 May 9. PMID: 25780857.
    • Abshire T, Cox-Gill J, Kempton CL, Leebeek FW, Carcao M, Kouides P, Donfield S, Berntorp E. Prophylaxis escalation in severe von Willebrand disease: A prospective study from the von Willebrand disease prophylaxis network. J Thromb Haemost. 2015 Apr 30. doi: 10.111/jth.12995. [Epub ahead of print]. PMID: 25930155.
    • Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR; Zimmerman Program Investigators. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015 Apr 2;125(14):2297-304. Doi: 10.1182/blood-2014-11-610824. Epub 2015 Feb 6. PMID: 25662333.

This website uses cookies to ensure you get the best experience on our website. Learn more